Theoretical Approaches to Lentiviral Mediated Neurotrophin Delivery in Potential Treatments of Parkinson’s Disease

Anam Qudrat*, Netra Unni*

*Institute of Biomaterials and Biomedical Engineering (IBBME), University of Toronto, Toronto, Canada

INTRODUCTION

Parkinson’s disease (PD†) is a late-onset neurodegenerative disease, characterized by both motor and non-motor symptoms. Motor symptoms include freezing, postural instability, rigidity, and tremor, while non-motor symptoms include anxiety, dementia, and depression [1]. Pathologically, it involves the loss of dopaminergic neurons in the nigrostriatal pathway (located in the midbrain) and the widespread accumulation of Lewy bodies (intracellular aggregates of the alpha-synuclein protein) in the central and peripheral nervous systems [2] that cause local inflammation. Furthermore, many areas of the midbrain also experience a drastic depletion of the neurotransmitter dopamine [3].

Currently, an array of potential treatments exist, attempting to target the above mechanisms. Prevailing therapeutics include small molecule inhibitors targeting gene expression of both the leucine-rich repeat kinase (LRRK2) gene as well as the alpha-synuclein (SNCA) gene [4], protein delivery mechanisms and gene therapy approaches to deliver neurotrophic factors like neurturin (NRTN) and glial cell line-derived neurotrophic factor (GDNF) [5,6], transplantation of totipotent stem cells in adult brains and anti-inflammatory drugs like coenzyme Q, minocycline, and caspase (which induces apoptosis) along with pathway inhibitors, all aimed to provide neuroprotective effects [5,7,8]. Although some of the proposed techniques temporarily alleviate symptoms, a non-invasive, target-specific treatment that will lead to long-term remission is ideal. Furthermore, some of the proposed treatments have not yet been implemented in clinical use.

†Abbreviations: PD, Parkinson’s disease; LRRK2, leucine-rich repeat kinase 2; SNCA, alpha-synuclein; NRTN, neurturin; GDNF, glial cell line-derived neurotrophic factor; PINK1, PTEN-induced putative kinase 1; PER1, period circadian clock 1; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; CNS, central nervous system; NGF, nerve/neural growth factor; BDNF, brain-derived neurotrophic factor; NT-3, neurotrophin-3; TNFa, tumour necrosis factor alpha; BBB, blood brain barrier; PEP-1-HO-1, PEP-1-hemeoxygenase-1; ROS, reactive oxygen species; GF, growth factor; NTR, neurotrophin; EGF, epidermal growth factor; LGF, liver growth factor; IGF-1, insulin-like growth factor 1; TGFα, intrastrial transforming growth factor alpha; FGF20, fibroblast growth factor 20; AAV2, adeno-associated virus type 2; 6-OHDA, 6-hydroxydopamine; HIV, human immunodeficiency virus; SCID-X1, X-linked severe combined immunodeficiency; VSV-G, vesicular stomatitis virus; hDAAC, human aromatic L-amino acid decarboxylase; MFT, fluoro-L-M-tyrosine; DA, dopamine; GAD, glutamic acid decarboxylase; UPDRS, unified PD rating scale; RRV, ross river virus; LCMV, lymphocytic choriomeningitis virus; RD114, feline endogenous retrovirus; GFAP, glial fibrillary acidic protein.

Keywords: Parkinson’s disease, lentivirus, neurotrophin, microglia, alpha synuclein

Author Contributions: Qudrat conceived the idea, provided resources/tools to complete the project and co-wrote the paper. Unni co-wrote the paper and contributed the tables and figure.
The following sections detail the fundamental components underlying the etiology of this multi-system neurodegenerative disorder.

Disease Pathophysiology

The pathophysiology has been linked to four distinct mechanisms: the formation of intraneuronal inclusions known as Lewy bodies (aggregates of the alpha-synuclein protein), genetic mutation in various genes such as \textit{LRRK2}, \textit{PIN1}, \textit{SNCA}, PRKN and the development of chronic inflammation as a result of oxidative and proteolytic stress, eventually leading to the degeneration of dopaminergic neurons in the substantia nigra pars compacta \cite{4,9,10}.

Lewy Bodies

The widespread accumulation of Lewy bodies in the central and peripheral nervous systems is an essential neuropathological characteristic of PD progression. The major constituent of Lewy bodies is the protein alpha-synuclein. Spillatini et al. (1998) utilized immunohistochemistry techniques to verify the presence of alpha-synuclein. The use of the primary antibody, \textit{PER1} (an anti-alpha-synuclein antibody) and the secondary anti-ubiquitin antibody enabled complete and strong staining of Lewy bodies in the midbrain tissues of patients with PD. Their findings suggested that these protein aggregates contain full-length or close to full-length alpha-synuclein, forming a majority of the abnormal filaments that constitute Lewy bodies \cite{11}.

Located on chromosome 4, alpha-synuclein is encoded by the \textit{SNCA} gene. A mutation in this gene has been associated with familial cases of PD. The protein is present in both water-soluble and lipid-based neurological tissues, allowing its existence in the intra-neuronal environment \cite{12}. It is abundant in the synapse and believed to play a role during synaptic vesicle release \cite{11}. The protein exists as a monomer and aggregates by forming oligomers and fibrils, subsequently \cite{13}. A prominent hypothesis in the mechanism of neuronal cell death, induced by Lewy bodies, involves the caspase 3-mediated apoptotic cascade \cite{14,15}. Figure 1 outlines possible pathways of alpha-synuclein aggregation in a neuron containing wild-type alpha-synuclein and mutated alpha-synuclein.

Genetic Mutations

Although there are cases of both sporadic and familial PD, current research exemplifies increasing evidence of genetic mutations as a significant contributing factor to the pathogenesis of PD. Specifically, the two main target genes are \textit{LRRK2} and \textit{SNCA}.

The \textit{LRRK2} gene codes for is a leucine-rich repeat kinase known as dardarin. The gene product also plays a role in many biological interactions including the retrograde trafficking pathway for recycling proteins, synaptic
vessel release and protein phosphorylation, which has been postulated to play a central role in PD [3]. Berg et al. (2005) conducted a clinical study with 53 unrelated families and found that mutations of the LRRK2 gene accounted for approximately 13 percent of apparently autosomal dominantly inherited PD. Thus far, a total of 10 missense mutations and one splice site mutation have been described with respect to the LRRK2 gene.

With regards to the SNCA gene, researchers strongly believe that the mutations in this gene are responsible for the aggregation of α-synuclein and hence the formation of intraneuronal Lewy bodies. In autosomal dominantly inherited cases, it was observed that a pathogenic missense mutation in SNCA contributed to approximately 2.5 percent of cases, resulting in it being a rare causal PD gene [9].

**Inflammation and Microglial Activation**

Inflammation is observed as a result of oxidative or proteolytic stress, the activation of microglia, as well as the upregulation of cytokines in the midbrain and cerebrospinal fluid [16].

The pathways essentially follow a cause-effect loop. When dying neurons are faced with an imbalance in free-radical production, oxidative stress mounts in the cells. This stress leads to the activation of many transcription factors which in turn express genes either coding for or controlling the effect of inflammatory cytokines [17]. The inflammation further impacts the neuron’s functioning and induces cell death [18].

Chronic inflammation can also be induced as a result of the body’s natural response. The brain, particularly, is equipped with specialized immune cells known as microglia. Wu et al. (2002) discovered that the blocking of microglial activation by minocycline protects the nigrostriatal dopaminergic pathway that is characteristically targeted by parkinsonian toxins, such as 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). This suggests that inflammation as a result of microglial activation plays a key role in the pathogenesis of PD [8].

The primary, innate immune cells found within the central nervous system (CNS) are the microglia (brain-specific macrophages) that are capable of exhibiting two distinct phenotypes: the pro-inflammatory (M1) type or the anti-inflammatory (M2) type [16]. Under normal physiological conditions, the microglial cells are ramified and make contact with neuronal axons, synapses as well as other glial cells such as astrocytes [19]. These interactions facilitate the secretion of neurotrophic factors such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3) which promote neuronal growth and survival [20,21]. However, pathological conditions such as the formation of Lewy bodies in Parkinson’s disease can activate the M1 phenotype of mi-

| Growth Factor | Potential function | References |
|---------------|--------------------|------------|
| Neurturin     | Will reduce the degeneration of neurons and enable neurons to function more efficiently | Olanow et al., (2015), Bartus et al., (2013), Wang et al., (2012), Tantrever et al., (2010), Ye et al., (2007) |
| Neurotrophin  | Will enable quick and efficient integration of nigral grafts to the native neuronal tissue | Haque et al., (1996), Tong et al., (2009), Nagatsu et al., (2000), Mogi et al., (1999) and Ebadi et al., (1998) |
| Epidermal Growth Factor | Will upregulate the expression of EGF receptors and by extension increase afferent signals of dopaminergic neurons | Iwakura et al., (2005), Chen et al., (2011) and Pellecchia et al., (2013) |
| Liver Growth Factor | Will promote the proliferation and tissue regeneration in the substantia nigra pars compacta and other regions of dopaminergic neuron degeneration | Gobernado et al., (2013) and Reimers et al., (2012) |
| Insulin-like Growth Factor 1 | Will display neuroprotective effects and reduce cognitive impairment as a result of PD | Offen et al., (2001), Kim et al., (2012), Godau et al., (2010) and Mashayekhi et al., (2010) |
| Transforming Growth Factor | Will stimulate the proliferation, migration and differentiation of dopaminergic neurons in the striatum and substantia nigra | Cooper, Isacson (2004) and Estepejo et al., (2001) |
| Fibroblast Growth Factor 20 | Will enhance the survival of dopaminergic neurons in the substantia nigra and will increase the levels of alpha-synuclein protein in the neurons | Zhu et al., (2015), Xu et al., (2013), Satake et al., (2007) and Mizuta et al., (2008) |

References

Olanow et al., (2015), Bartus et al., (2013), Wang et al., (2012), Tantrover et al., (2010), Ye et al., (2007); Haque et al., (1996), Tong et al., (2009), Nagatsu et al., (2000), Mogi et al., (1999) and Ebadi et al., (1998); Iwakura et al., (2005), Chen et al., (2011) and Pellecchia et al., (2013); Gobernado et al., (2013) and Reimers et al., (2012); Offen et al., (2001), Kim et al., (2012), Godau et al., (2010) and Mashayekhi et al., (2010); Cooper, Isacson (2004) and Estepejo et al., (2001); Zhu et al., (2015), Xu et al., (2013), Satake et al., (2007) and Mizuta et al., (2008); Gobernado et al., (2013) and Reimers et al., (2012); Offen et al., (2001), Kim et al., (2012), Godau et al., (2010) and Mashayekhi et al., (2010); Cooper, Isacson (2004) and Estepejo et al., (2001); Zhu et al., (2015), Xu et al., (2013), Satake et al., (2007) and Mizuta et al., (2008)
eral growth factors have been tested to potentially treat cerebral disorders, a variety of gen-
tors and subsequently activating cell signaling cascades.

Although nerve/neural growth factors (GFs) are biological compounds that stimulate cellular re-
generation and thereby facilitate the process of healing. Furthermore, they attract macrophage progenitor cells (e.g., monocytes) from the bone marrow to migrate to the CNS and differentiate into active microglia [24,25]. Microglial proliferation and chronic activation, in turn, contribute to disease progression and deterioration of the patient’s quality of life.

Degeneration of D opaminergic Neurons

Although PD also results in the degeneration of other neurons, including serotonergic and noradrenergic, it has been observed that degeneration occurs to a large extent of dopaminergic neurons – specifically located in the substantia nigra pars compacta. The pathways discussed above work in conjunction to induce cell death in the neurons. Specifically, the formation of intraneuronal inclusions and chronic inflammation are the largest contributing factors to neuron degeneration. Neurotoxins, especially MPTP, are considered to be the leading cause of neuronal degradation [26].

Hirsch et al. found that a sub-population of dopaminergic neurons, stained by neuromelanin, are more susceptible to degradation. This is due to the fact that MPTP and its metabolite, MPP+ (responsible for neuronal deterioration), bind to neuromelanin [27]. Furthermore, Youn et al. demonstrated that the transduction of Pep-1-heme oxygenase-1 (Pep-1-HO-1) in human neuroblastoma SH-SYSY cells inhibited the production of reactive oxygen species (ROS). Intrapertoneal injection of Pep-1-HO-1 in PD mouse models significantly reduced the toxic effects of MPTP and MPP+. These findings suggest that Pep-1-HO-1 could be a viable agent in the treatment of oxidative stress-induced PD. Both studies exemplify the interdependent nature of PD pathogenesis on specific biological interactions. The onset of PD is incremental as each outlined mechanism appears to be a trigger of sorts for another [28].

Role of Neurotrophic Factors in PD

Due to the fact that PD is a neurodegenerative disor-
der, one of the most promising directions for therapeutic research is in reviving neurons using growth factors (GFs). GFs are biological compounds that stimulate cellular regeneration and thereby facilitate the process of healing. Although nerve/neural growth factors (NGFs) are commonly applied to treat cerebral disorders, a variety of general growth factors have been tested to potentially treat PD [6].

Growth factors function by binding to cellular receptors and subsequently activating cell signaling cascades that regulate mitosis, differentiation and apoptosis. Neur-
turin (NRTN), neurotrophin (NTR), epidermal growth fac-
tor (EGF), liver growth factor (LGF), insulin-like growth factor 1 (IGF-1), intrastriatal transforming growth factor alpha (TGFα) and fibroblast growth factor 20 (FGF20) are a few of the common GFs that have been tested to treat PD. Table 1 summarizes potential growth factors, their intended therapeutic function and existing papers which support the applications of these GFs.

NRTN is a naturally occurring analog of glial cell line-derived neurotrophic factors (GDNFs), commonly used to target dopaminergic neurons in the nigrostriatal pathway of PD animal models [29]. Its observed effects include delay of neuron degeneration, selective protection of dopaminergic neurons and general enhancement of neural functioning [30]. Currently, it is also believed that the levels of docosahexaenoic acid (DHA, a major polyunsaturated fatty acid in the brain) alters levels of NRTN [31]. Gasmi et al. (2007) conducted animal trials to achieve striatal delivery of NRTN by using CERE-120 (an adeno-associated virus type 2 - AAV2). Viral vector-mediated delivery of NRTN genes has since been an increasingly targeted mechanism of therapy for PD [32]. Olanow et al. (2015) recently conducted a double-blind, randomized, controlled trial to measure the efficacy of AAV2 as a vehicle for NRTN delivery to the substantia nigra and the putamen. Post-mortem testing found that NRTN was expressed in the putamen, bilaterally; however, minimal expression was observed in the substantia nigra pars compacta (SNC). Researchers hypothesized that a delayed response to AAV2-NRTN was observed due to impaired transport from the putamen to the cell bodies in the SNC, characteristic of PD [5].

NTR was also found to have promising effects in idiopathic cases of PD. Studies have observed that apoptotic cascades in Parkinsonian patients are also correlated with decreased levels of NTR [2,33]. Within the CNS, NTR functions by improving the efficacy of nigral grafts [34,35]. Haque et al. tested the application of NTR4/5 to increase the survival of dopaminergic neurons in ventral mesencephalic tissue grafts. Transplantation of such grafts in the substantia nigra has been a method of treatment for PD. Haque’s study found that the infusing of NTR4/5 (but not NTR3) stimulated fibre growth and enhanced the functionality of the nigral grafts [36]. Furthermore, it is worth noting that the increased efficacy was observed in vivo, suggesting that the application of NTR to facilitate neuron regeneration and surgical graft integration is a viable option to alleviate PD-associated symptoms in the long term.

Aside from the described NGFs, general growth factors, including EGF and LGF, have also been applied in the context of PD. Iwakura et al. explored the role of EGF in PD. EGF exerts neurotrophic activity on dopaminergic neurons in the midbrain. Iwakura’s results demonstrated that the expression of EGF receptors were downregulated in the post-mortem brains of PD patients. These findings are indicative of EGF’s neurotrophic activity being mod-
ulated by afferent signals of dopaminergic neurons [37]. Additionally, EGF’s activity is further impaired by neural degeneration that is characteristic of PD, making EGF a potential target for therapeutics [38,39].

Gobernado et al. observed neuroprotective activity when LGF was administered, peripherally, in a rat model of PD [40]. LGF is a hepatic mitogen that promotes proliferation of various cell types and facilitates tissue regeneration. Upon peripheral application of LGF to the 6-hydroxydopamine (6-OHDA)-injected region in the left striatum, unilaterally, sprouting of tyrosine hydroxylase-positive terminals and dopamine transporter expression was increased. LGF also stimulated the phosphorylation and regulation of proteins critical for cell survival - including Bcl2 and Akt. Due to the partial protection LGF provides dopaminergic neurons from 6-OHDA neurotoxicity and alleviation of motor-based symptoms in the PD rat models, along with improved efficacy of nigral grafts, LGF could be administered to treat PD [7].

Insulin-like growth factor 1 (IGF-1) provides neuroprotective effects through its anti-apoptotic properties that mainly target the endoplasmic reticulum in neurons [41,42]. Godau et al. found that IGF-1 could be a serum marker for early PD and could therefore play a critical role in earlier diagnosis of PD [43]. Additionally, it was also observed that IGF-1 may assist in neuronal protection from toxic substances that are characteristic of PD, particularly DA-induced toxicity [44].

Intrastratial delivery of transforming growth factor alpha (TGF-α) has been shown to significantly stimulate the proliferation and substantial migratory waves in dopamine-denervated rats [45]. Furthermore, intrabrain transplantation of TGF-β1 gradually improved the overall condition of parkinsonian rats through striatal reinnervation and increase of dopamine levels in the grafted striatum [46].

Fibroblast growth factor 20 (FGF20) is substantially expressed in the substantia nigra and is believed to play a crucial role in the protection of dopaminergic neurons [47]. Specifically, it was found that the FGF20 gene rs1721100 polymorphism is associated with an elevated PD risk [48,49]. Mizuta et al. also found that FGF20 had a significant presence in the SNCA homozygote (risk allele). SNCA is the gene that codes for alpha synuclein (the primary constituent of Lewy Bodies) [50]. FGF20 and SNCA work synergistically, suggesting that FGF20 could alleviate PD symptoms by interfering with the mechanism of Lewy Body formation.

AN INTRODUCTION TO RETROVIRAL-BASED GENE DELIVERY SYSTEMS

Retroviral vector-mediated gene delivery is an area of gene therapy that has gained increasing attention over the past decade to deliver genes to target cells using viral particles as vehicles [51]. Lentiviruses belong to the Retroviridae family of viruses and are especially useful in introducing genes into the host DNA. An example of a lentivirus genome that has been widely exploited is the human immunodeficiency virus (HIV) genome that consists of structural genes called gag, pol and env that package the viral core, regulatory genes named tat and rev that are involved in viral replication as well as accessory genes known as vif, vpr, vpu, and nef involved in viral growth and propagation in vivo [52]. Once the target genes are packaged into these viral vectors, they convert their single stranded RNA into a double stranded DNA that can stably integrate into the host genome. The integrated vector, called the provirus, undergoes replication and transcription in the host genome producing the viral mRNAs and the packaged RNA as well [53]. The advantage of using lentiviruses is that they allow for the stable integration of genetic material in non-dividing, terminally differentiated cells [53,54]. Specifically, lentiviral-based vector delivery systems have been used in vivo to target various diseases, ranging from blood-borne diseases like X-linked severe combined immunodeficiency (SCID-X1) [53], skeletal muscle disorders like Duchenne muscular dystrophy [55], cancer immunotherapy, [51] to neurodegenerative diseases such as Parkinson’s disease [8], among others.

Development of Safer, Viable Vector Systems

However, since the initial development of lentiviral-based vector delivery systems, both vector performance and safety issues have risen time and time again. Because there is an active and dynamic contact with the host genome, threats of oncogene activation and insertional mutagenesis through the activation of non-specific endogenous promoters encroach vector applicability [56,53,57]. To address these concerns, research in viral vector development has picked up and delivered safer options, specifically exploiting the structure of the viral particle. The human immunodeficiency virus (HIV) has been extensively studied and the genome has been manipulated in order to safely use this virus as a research tool. Genes encoding the various viral components were either expressed through separate plasmid constructs, removed, modified in orientation/conformation, repressed (i.e., self-inactivating constructs) or adapted from other viruses to tone down virulence while still retaining adequate efficacy [56,57]. Adapting a vector system from a primate model confers the added advantage of potentially reducing an immune response.

The first generation development of these viruses involved a different viral envelope than HIV, specifically the G protein of the vesicular stomatitis virus (VSV-G) adapted to coat the virus. Known as pseudotyping, this can be exploited as a targeting mechanism if the coat is genetically modified to bind specific proteins/receptors of a tissue subpopulation. The second generation vectors limited the vector packaging component to four essential genes, namely gag, pol, tat and rev. The third generation
of vectors, placing rev in a trans conformation, allows the production of high titre gag and pol thus dispensing tat as well [52]. Thus, vectors, initially derived from the human immunodeficiency virus (HIV), have been modified with the removal of regulatory and accessory genes that encode virulence factors [51]. Hence, a replication-defective lentiviral particle has been created with a viral core consisting of structural proteins and enzymes, an envelope of an unrelated virus and the lentiviral genome. Over the years, lentiviral systems have been developed to offer certain advantages over other competing viral vector systems such as the ability to transduce dividing as well as non-dividing cells, demonstrate long-term, stable gene expression, and safely infect target cells at a high efficiency [58].

Exploiting this efficient delivery system for cell-based therapeutics is an emerging field. Using the lentiviral-based gene therapy as a tool, one can exploit the potential of engineering cells to sense, “process,” and respond to a dynamic environment [59]. It is well established that in HIV infected individuals, the virus does reach the CNS via infected macrophages that cross the blood brain barrier [53]. Although the mechanism of CNS pathology continues to be explored, it is known that the env and tat proteins cause neurotoxicity in vitro [53]. Therefore, viral vector technology aids one to develop a recombinant, replication-deficient viral particle that delivers a therapeutic gene to a specific cell population efficiently.

**VECTOR TARGETED DELIVERY TO THE CNS**

Whereas an ex vivo approach is aimed at modifying the target cell population outside of the body and then reintroducing the cells via implantation, an in vivo approach uses vector delivery systems such as the lentiviral vector system to deliver the therapeutic gene allowing for the direct manipulation and establishment of stable, long-term control in a non-dividing neuronal population by permanently integrating into the host cell population. Lentiviral vectors are particularly advantageous due to their large cloning capacity of 8 to 10 kilobase pairs. The therapeutic gene can act on various levels such as binding

### Table 2. An overview of clinical trials testing viral vector delivery

| Viral Vector and Gene | Limitations | Proposed Improvements | References |
|-----------------------|-------------|-----------------------|------------|
| AAV-hDAAC (human L-amino acid decarboxylase) | Lack of control for result comparison. Non-blinded analysis increased difficulty of result interpretation. DA levels not measured. | Progress is limited as the results did not show significant improvement. A well-defined control and double-blind analysis would improve result interpretation. | Eberling et al., (2008) |
| CERE-120 (AAV serotype 2 - NRTN) | Secondary measures of motor function did not show significant improvement. | Good tolerance of the treatment, without any clinically significant adverse effects was observed. More specific facets of measuring motor function could be employed. | Marks et al., (2008) |
| AAV2-NRTN | Many patients developed severe adverse reactions due to surgical procedure. No significant change in comparison with control. | Demonstrated that gene therapy results in long-term gene expression. Increased sterilization and minimally invasive surgical procedures would reduce design limitations. | Marks et al., (2010) |
| AAV2-GAD | Mild adverse reactions occurred for most patients. One severe adverse reaction was reported. | Majority of PD patients receiving the AAV2-GAD treatment had a significant improvement from their baseline UPDRS score. Adverse reactions can be overcome by introducing more rigorous evaluation of treatment. | LeWitt et al., (2011) |
| ProSavin | Cases of mild on-medication dyskinesia and on-off phenomena reported. | Reduction in resting tremors and increased motor control found. Treatment was well-tolerated and safe. Further research should be conducted to determine potential sources of on-off phenomena. | Palif et al., (2014) |
and inhibiting the mRNA of the dysfunctional, target gene or binding the protein itself [60]. Going one step further, it is possible to achieve temporal and spatial control of these vectors using transgenic or knock-out/knock-in models. Ideally, the proposed viral vector should be specifically targeted to the host population and not generate an immunological response.

Practical elements to consider when generating a targeted viral vector to the brain include selection of viral serotype (i.e., groups sharing specific surface molecules) and injection dose and site. In particular, pseudotyping with various viruses such as the VSV and Mokola virus leads to CNS transduction [61]. The use of a chimeric viral vector system was recently applied to cure two distinct types of brain tumors in mice [62]. The virus VSV-G, with its broad tropism, readily infects tumor cells but causes widespread neurotoxicity in the brain, even when expression is attenuated via mutations. The viral vector VSV-LASV-GPC, encoding the wildtype VSV from the Indiana serotype for the G protein, was fused with the Lassa fever virus glycoprotein gene with a GFP reporter gene engineered on the C-terminus for visualization. When tested, this chimeric vector showed reduced infection of normal glia and neuronal cells versus tumor cells (i.e., gliomas) creating in vivo target specificity. Intracranial or intravenous (tail-vein) injections in mouse models showed target specificity as VSV targeted brain tumors. Normal cells were protected due to the activation of type I interferon (a large group of interferon proteins that regulate innate immune system activity) as compared to tumor cells [62]. Safe vector dosages range from $10^2$ to $10^6$ transducing viral units [62,63]. Taking such practical considerations into effect can increase the efficacy of the target vector delivery system.

An Overview of NGF-Based Clinical Trials for Parkinson’s Disease

Currently, the vast majority of clinical trials for Parkinson’s disease employ the use of adeno-associated viruses to deliver neurotrophic factors in order to provide neurotrophic support and have not progressed beyond Phase II [64–68]. Although the lentiviral approach has shown relative success when applied to primate model systems [69–71] in the past, no adequate results were reported from ongoing clinical trials. Along with certain methodological limitations, as outlined in Table 2, perhaps the drawbacks observed in clinical trials is due to our limited understanding of lentiviral effects in vivo. Furthermore, the measurement of long term effects of stable neurotrophic factors has not been incorporated, in a rigorous manner, in a majority of the clinical trials outlined below.

Eberling et. al conducted bilateral infusion of an AAV containing the human aromatic L-amino acid decarboxylase (hDAAC) gene, into the putamen of patients with moderate to advanced levels of PD [64]. Low doses of the AAV-hDAAC injection produced an average of 30 percent increase in fluoro-L-M-tyrosine (FMT) (an in vivo measurement of gene expression). A primary downfall of the study was the fact that a control was not utilized. Furthermore, the study itself states that “nonblinded analyses make interpretation difficult.” The transfection of hDAAC into nondegenerating striatal neurons is expected to convert low doses of L-dopa (a precursor of dopamine) into high levels of DA. The study, however, was unable to directly quantify levels of DA, creating questionable results that must be interpreted cautiously [64].

Marks et. al (2008) initially conducted a phase I clinical trial to determine the safety and tolerability of CERE-120 (AAV serotype 2 – NRTN). Patients with idiopathic PD received bilateral, intraputaminal injections of the vector. The results primarily showed good tolerance of the treatment, without any clinically significant adverse effects within a year after injection. The study claims that several “secondary measures of motor function” showed improvement – including a mean improvement in the off-medication motor subscore; however, the improvements were not significant [66].

Marks et. al (2010) also conducted a double-blind, randomized, controlled trial for the gene delivery of AAV2-NRTN. A cohort of advanced PD patients were randomly assigned to receive either AAV2-NRTN (injected bilaterally into the putamen) or a sham surgery. The results found that there was no significant difference between patients treated with AAV2-NRTN and the control group. Furthermore, 13 out of 38 patients treated with AAV2-NRTN developed severe adverse reactions (mainly due to the surgical process). Although the results themselves did not provide any significant benefit, the study was able to show that gene transfer enables long-term gene expression. However, this property means that patients must be followed-up frequently upon receipt of the procedure [65].

The primary drawback of the above studies mainly relates to the surgical techniques and injection mechanisms employed to deliver the lentiviral vector. A significant proportion of adverse reactions (e.g. intracranial hemorrhaging) were believed to have occurred as a result of surgical procedures [72]. Currently, procedures include vertical administration of the vector from the dorsal surface of the brain and identification of intraputaminal targets using the Leksell stereotactic frame and MRI guidance [73]. These procedures, however, can cause unintended effects without employing a meticulous and methodical approach. For example, increased precision can be achieved using localization software, enabling more efficient targeting.

Nevertheless, despite the lack of success with pre-existing lentiviral-mediated delivery of neurotrophic factors, ProSavin clinical trials show a promising avenue for future development. ProSavin is an experimental drug that uses a lentivector delivery system to transfer genes to the
striatum. Palfi et al. (2014) bilaterally injected ProSavin into the putamen of PD patients. A series of three different doses were utilized. In the first 12 months, mild drug-related adverse reactions were reported, mainly consisting of on-medication dyskinesia and off-on phenomena. Results suggested that ProSavin administration was safe and well-tolerated. Furthermore, motor improvement, including reduced resting tremors and increased motor control, were observed in all patients [73].

LeWitt et al. (2011) attempted to compare the efficacy of gene transfer of glutamic acid decarboxylase (GAD) with sham surgery. Patients with progressive levodopa-responsive PD received bilateral injection of AAV2-GAD to the subthalamic nucleus. It was hypothesized that similar to animal models, GAD would improve basal ganglia function. The study also showed promising results as a majority of PD patients receiving the AAV2-GAD treatment had a significant improvement from their baseline unified PD rating scale (UPDRS) score. The study also showed safety of the treatment, as the most common adverse reactions were mild, including nausea and headaches [68].

We propose that in vivo gene therapy, primarily using lentiviral vehicles, is a promising therapeutic approach, despite the inadequate results produced by existing clinical trials. Primary advantages of this approach include permanent changes of the neuron’s genome. Most of the wild-type genome of the virus is deleted, resulting in minimal toxicity. Additionally, invasiveness of the therapy is decreased as only one injection to the site is required, contrary to multiple injections that would result if the neuron was unable to produce its own neurotrophic factors. Currently, most clinical trials employ bilateral injection of the vector to the putamen or the striatum. Perhaps novel injection techniques can be determined to increase the efficacy of lentiviral vectors and to reduce surgery-associated adverse events [72,74]. Table 2 shows a summary of clinical trials and a brief analysis of their successes and drawbacks.

An Example of a Lentiviral-Based Delivery System

Delivery mechanisms for gene therapy differ in their targeting scope with some targeting widespread target populations such as direct injection, while others are more specific to certain subpopulations such as pseudotyping (for example, brain region vs. glial cell population). The convention is to use direct injection protocols either into the retina or brain that bypass the blood brain barrier [74]. Other than being an invasive technique, a lower transfection efficiency and the need for high viral titres offset the potential applicability of direct injection. On the other hand, pseudotyping can achieve acute target specificity with viral coats that can easily transduce specific cell types such as haematopoietic stem cells (using Feline leukemia virus) and neuronal cells (Ross river virus) [75]. The most widely used glycoprotein for pseudotyping is VSV-G due to its broad tropism and stability [76]. This broad tropism is achieved by the glycoprotein attaching to a ubiquitous cell receptor. However, to achieve cellular specificity, glycoproteins exist that are targeted to specific cell types or organs - for example, targeting Ross River virus (RRV) to Kupffer cells of the liver, Ebola virus to lung, the lymphocytic choriomeningitis virus (LCMV) to pancreatic islet cells, the Mokola virus to cardiomyocytes of muscle tissue and the Feline endogenous retrovirus (RD114) to the hematopoteic system among others [76]. Going one step further, instead of adopting these coats from existing viruses, it is possible to engineer these coats to obtain cell-type specificity. Such an approach allows one to modify the viral surface with proteins (i.e., cell-specific peptides or antibodies). In addition, using mammalian promoters such as synapsin 1 and glial fibrillary acidic protein (GFAP) to drive expression of lentiviral vectors to targets have been used previously [77].

In the lentiviral transgene cassette, we propose to include a microglia-specific promoter and an anti-α-synuclein antibody. Candidate microglial specific promoters that are well characterized in humans include NGF from -600 to +250 nucleotides [75] and BDNF exon III from +2623 to +3028 nucleotides [77,78]. A candidate anti-α-synuclein antibody is PER1 under the control of the strong human cytomegalovirus (CMV) promoter to initiate high level stable mammalian expression. Specifically, PER1 is a synthetic antibody synthesized against residues 11-34 of α-synuclein and thus exclusively recognizes the “α” isoform of the synuclein protein. While the microglia specific promoter provides cellular specificity, the antibody will provide therapeutic benefits. To assess any benefits, the amount of debris (i.e., unfolded protein) removed from the CNS should be determined periodically every few months. Using the doxycycline regulatory system [18,78] and the fluorescent cassette strategy [79], the promoter/gene functionality needs to be controlled and validated in vitro before moving on to mouse models.

Previously, Recchia et al. (2007) were able to induce some of the prevalent symptoms of PD in rat models through the intranigral injection of TAT-α-synA30P (a transduced protein construct). The usage of a transduction domain derived from HIV enabled the construct to diffuse through the neuronal membrane, resulting in selective dopaminergic loss and long-term motor deabilites. Particularly, it was found that the novel method of α-synuclein integration induced symptoms associated with the early stages of PD in rat models [80]. Using these findings and two other Parkinson’s disease models with nigral synucleinopathy, one can measure the efficacy of the delivery system in vivo, when employed intravenously. Whereas the AAV-α-synuclein viral model mimics the disease genotype, the inducible drug-based MPTP model illustrates the disease phenotype. Specifically, the AAV-α-synuclein viral model activates the adaptive immune response stimulating microglial proliferation [81]. On the
other hand, the MPTP model causes nigrostrial neuronal loss leading to Parkinson’s disease motor symptoms such as rigidity, tremor, and gait and posture abnormality.

**CONCLUDING REMARKS**

Herein, we have provided a potentially applicable model system wherein a lentiviral-based delivery tool can be engineered to target and alleviate Parkinson disease symptoms. Using this approach ensures that viral vectors can transduce changes in non-dividing neuronal cells of the brain. The delivery of neurotrophic factors to the brain alleviates the inflammatory stress induced by the CNS innate immune system. With long-term stability and integration, the therapeutic potential of vectors are significant. Nevertheless, the long term effects of expressing neurotrophic factors needs to be readily assessed alongside to avoid other detrimental side effects, such as overexpression of genes. Potential methods to assess the future effects of stably expressed neurotrophins include monitoring immunoreactivity and utilizing staining techniques to observe and predict the occurrences of on-target and off-target effects [82,83]. Although issues of vector genotoxicity may still exist and the field may be far from addressing patient-specific needs, with the development of cell-specific gene therapy techniques, we are establishing a framework on which to build a comprehensive therapeutic approach.

**REFERENCES**

1. Petrucelli L, Dickson DW. Neuropathology of Parkinson’s Disease. In: Nass R, Przedborski, S, editors. Parkinson’s Disease. Amsterdam: Elsevier/Academic Press; 2008. p. 35-48.
2. Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines and neurotrophins in Parkinson’s disease. J Neural Transm Suppl. 2000;(66):277-90.
3. Tan LCS. Epidemiology of Parkinson’s disease. Neurol Asia. 2013;18(3):231-8.
4. Nuytemans K, Theuns J, Cruts M, van Broeckhoven C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update. Hum Mutat. 2010;31(7):763-80.
5. Warren Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol [Internet]. 2015;93(3):335-44. Available from: http://doi.wiley.com/10.1002/ana.24436
6. Barker RA. Parkinson’s disease and growth factors -- are they the answer? Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S181-4.
7. Reimers D, Osuna C, Gonzalez-Gobedaro R, Herranz AS, Diaz-Gil JJ, Jimenez-cescrig A, et al. Liver growth factor promotes the survival of grafted neural stem cells in a rat model of Parkinson’s disease. Curr Stem Cell Res Ther. 2012;7(1):15-25.
8. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadsath C, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci. 2002;22(5):1763-71.
9. Berg D, Schweitzer KJ, Leitner P, Zimprich A, Lichtner P, Belcredi P, et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson’s disease*. Brain. 2005;128(Pt 12):3000-11.
10. Alexander GE. Biology of Parkinson’s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin Neurosci. 2004 Sep;6(3):259-80.
11. Spillantini MG, Crowther RA, Jakks R, Hasegawa M, Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A. 1998;95(11):6469-73.
12. Breyo L, Wu JW, Uversky VN. α-Synuclein misfolding and Parkinson’s disease. Biochim Biophys Acta. 2012;1822(2):261-85.
13. Maries E, Dass B, Collier TJ, Kordower JH, Stacey-Collier K. The role of α-synuclein in Parkinson’s disease: insights from animal models. Nat Rev Neurosci. 2003; 4(9):727-38.
14. Kaul S, Anantharam V, Kanthasamy A, Kanthasamy AG. Wild-type α-synuclein interacts with pro-apoptotic proteins PKCδ and BAD to protect dopaminergic neuronal cells against MPP⁺-induced apoptotic cell death. Brain Res Mol Brain Res. 2005;139(1):137-52.
15. Bilisland J, Roy S, Xanthoudakis S, Nicholson DW, Han Y, Grimm E, et al. Caspase inhibitors attenuate 1-methyl-4-phenylpyridinium toxicity in primary cultures of mesencephalic dopaminergic neurons. J Neurosci. 2002;22(7):2637-49.
16. Cappellano G, Careccchio M, Fleetwood T, Magistrelli L, Cantello R, Dianzani U, et al. Immunity and inflammation in neurodegenerative diseases. Am J Neurodegener Dis. 2013;2(2):89-107.
17. Ferrari CC, Tarelli R. Parkinson’s disease and systemic inflammation. Parkinsons Dis. 2011;2011:436813.
18. Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14(7):463-77.
19. Kettenmann H, Hanisch UK, Noda M, Verkhatsky A. Physiology of microglia. Physiol Rev. 2011;91(2):461-553.
20. Nakajima K, Honda S, Tohyama Y, Imai Y, Kohsaka S, Kurihara T. Neurotrophin secretion from cultured microglia. J Neurosci Res. 2001;331(September 2000):322-31.
21. Nakajima K, Tohyama Y, Maeda S, Kohsaka S, Kurihara T. Neuronal regulation by which microglia enhance the production of neurotrophic factors for GABAergic, catecholaminergic, and cholinergic neurons. Neurochem Int. 2007;50(6):807-20.
22. Chang MY, Chan CK, Braun KR, Green PS, O’Brien KD, Chat A, et al. Monocyte-to-macrophage differentiation: Synthesis and secretion of a complex extracellular matrix. J Biol Chem. 2012;287(17):14122-35.
23. Kettenmann H, Kirchhoff F, Verkhratsky A. Microglia: New Roles for the Synaptic Stripper. Neuron. 2013;77(1):10-18.
24. Soulet D, Rivest S. Bone-marrow-derived microglia: myth or reality? Curr Opin Pharmacol. 2008;8(4):508-18.
25. Hinze A, Stolzing A. Differentiation of mouse bone marrow derived stem cells toward microglia-like cells. BMC Cell Biol. 2011;12:35.
26. Reynolds AD, Stone DK, Hutter JL, Benett EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol. 2010;184(5):2261-71.
27. Hirsch EC, Hunot S, Damier P, Fauchoux B. Glial cells and inflammation in Parkinson’s disease: a role in neurodegeneration? Ann Neurol. 1998;44(3 Suppl 1):S115-20.
28. Youn JK, Kim DW, Kim ST, Park SY, Yeo EJ, Chay YJ, et al. PeP-1-HO-1 prevents MPTP-induced degeneration of dopaminergic neurons in a Parkinson’s disease mouse model. BMB Rep. 2014;47(10): 569-574.
29. Ye M, Wang XJ, Zhang YH, Lu GQ, Liang L, Xu JY, et al. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson’s disease. Brain Res. 2007;1142:206-16.
30. Wang W, Sun M, Li H, Wang W, Van M. The delivery of tyrosine hydroxylase accelerates the neurorestoration of Macaca rhesus model of Parkinson's disease provided by Neuturin. Neurosci Lett. 2012;524(1):10-15.
31. Tanriover G, Seval-Celik Y, Ozsoy O, Akkoynuoglu G, Savcioglu F, Hacioglu G, et al. The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease. Folia Histochim Cytochonobiol. 2010;48(3):434-41.
32. Gasmi M, Brandon EP, Herzog CD, Wilson A, Bishop KM, Hofer EK, et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis. 2007;27(1):67-76.
33. Mogi M, Togari A, Kondo T, Mizioz Y, Komure O, Kuno S, et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett. 1999;270(1):45-8.
34. Ebadi M, Ramana Kumari MV, Hiramatsu M, Hao R, Pfeiffer RF, Rojas P. Metallothionein, neurotrophins and selegiline in providing neuroprotection in Parkinson's disease. Restor Neurol Neurosci. 1998;12(2-3):103-11.
35. Tong M, Dong M, De La Monte SM. Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with lewy bodies: Potential role of manganese neurotoxicity. J Alzheimers Dis. 2009;16(3):585-99.
36. Haque NSK, Hlavin ML, Fawcett JW, Dunnett SB. The neurotrophin NT4/5, but not NT3, enhances the efficacy of nigral grafts in a rat model of Parkinson's disease. Brain Res. 1996;712(1):45-52.
37. Iwakura Y, Piao YS, Mizuno M, Takei N, Kakita A, Takanashi H, et al. Influences of dopaminergic lesion on epidermal growth factor-erbB signals in Parkinson's disease and its model: Neurotrophic implication in nigrostriatal neurons. J Neurochem. 2005;93(4):974-83.
38. Pellecchia MT, Santangelo G, Picillo M, Pivonello R, Longo K, Pivonello C, et al. Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. J Neurol. 2013;260(2):438-44.
39. Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann G, Hurtig HI, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol. 2011;69(4):655-63.
40. Gonzalo-Gobernado R, Calatrava-Ferreras L, Reimers D, Herranz AS, Rodriguez-Serrano M, Miranda C, et al. Neuroprotective Activity of Peripherally Administered Liver Growth Factor in a Rat Model of Parkinson's Disease. PLoS One. 2013;8(7):e76771.
41. Kim Y, Li E, Park S. Insulin-Like Growth Factor-1 Inhibits 6-Hydroxydopamine-Mediated Endoplasmic Reticulum Stress-Induced Apoptosis via Regulation of Heme Oxogense-1 and Nrf2 Expression in PC12 Cells. Int J Neurosci. 2012;122(11):641-9.
42. Mashayekhi F, Mirzajani E, Naji M, Azari M. Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson's disease. J Clin Neurosci. 2010;17(5):623-7.
43. Godau J, Herfurth M, Kattner B, Gasser T, Berg D. Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010;81(5):536-8.
44. Offen D, Shtair B, Hadad D, Weizman A, Melamed E, Gil-Ad I. Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: Possible implications for Parkinson's disease. Neurosci Lett. 2001;316(3):129-32.
45. Cooper O, Isaacson O. Intrastriatal transforming growth factor alpha delivery to a model of Parkinson's disease induces proliferation and migration of endogenous adult neural progenitor cells without differentiation into dopaminergic neurons. J Neurosci. 2004;24(41):8924-31.
46. Espejo EF, Gonzalez-Albo MC, Moraes JP, El Banoua F, Flores JA, Caraballo I. Functional regeneration in a rat Parkinson's model after intrastriatal grafts of glial cell line-derived neurotrophic factor and transforming growth factor beta1-expressing extra-adrenal chromaffin cells of the Zuckerkandl's organ. J Neurosci. 2001;21(24):9888-95.
47. Satake W, Mizuta I, Suzuki S, Nakabayashi Y, Ito C, Watanabe M, et al. Fibroblast growth factor 20 gene and Parkinson's disease in the Japanese population. Neuroreport. 2007;18(9):937-40.
48. Zhu R, Zhu Y, Liu X, He Z. Fibroblast growth factor 20 (FGF20) gene polymorphism and risk of Parkinson's disease: a meta-analysis. Neurol Sci. 2014;35(12):1889-94.
49. Xu X, Wang N, Xu H, Xie A, Jiang H, Xie J. Fibroblast growth factor 20 polymorphism in sporadic Parkinson's disease in Northern Han Chinese. J Clin Neurosci. 2013;20(11):1588-90.
50. Mizuta I, Tsunoda T, Satake W, Nakabayashi Y, Watanabe M, Takeda A, et al. Calbindin D1, fibroblast growth factor 20, and alpha-synuclein in sporadic Parkinson's disease. Hum Genet. 2008;124(1):89-94.
51. Escors D, Brecqpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz). 2011;58(2):107-19.
52. Dull T, Zufferrey R, Kelly M, Kelly RJ, Nguyen M, Trono D, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463-71.
53. Anson DS. The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther. 2004;2:9.
54. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol. 2006;208(2):299-318.
55. Talbot GE, Waddington SN, Bales O, Tchen RC, Antoniou MN. Desmin-regulated lentiviral vectors for skeletal muscle gene transfer. Mol Ther. 2010;18(3):601-8.
56. Takeuchi Y. Lentivirus Gene Engineering Protocols. Br J Cancer. 2004;90(2):557.
57. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4(5):346-58.
58. Yi Y, Noh MJ, Lee KH. Current advances in retroviral gene therapy. Curr Gene Ther. 2011;11(3):218-28.
59. Fischbach MA, Bluestone JA, Lim WA. Cell-based therapeutics: the next pillar of medicine. Sci Transl Med. 2013;5(179):179ps7.
60. Persons DA. Lentiviral vector gene therapy: effective and safe? Mol Ther. 2010;18(5):861-2.
61. Watson DJ, Kobinger GP, Passini MA, Wilson JM, Wolfe JH. Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, ebola, Mokola, LCMV, or MuLV envelope proteins. Mol Ther. 2002;5(5 Pt 1):528-37.
62. Wollmann G, Droklyansky E, Davis JN, Cepko C, van den Pol AN. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors. J Virol. 2015;89(13):6711-24.
63. Abordo-adesida E, Follenzi A, Barcia C, Sciascia S, Castro MG, Naldini L, et al. Stability of Lentiviral Vector-Mediated Transgene Expression in the Brain in the Presence of Systemic Antivector Immune Responses. Hum Gene Ther. 2005;16(6):741-51.
64. Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology. 2008;70(21):1980-3.
65. Marks WJ, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(12):1164-72.
66. Marks WJ, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, et al. Safety and tolerability of intraputaminal de-
livery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. Lancet Neurol. 2008;7(5):400-8.

67. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology. 2009;73(20):1662-9.

68. LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, et al. AAV2-GAD gene therapy for advanced Parkinson’s disease: A double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011;10(4):309-19.

69. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science. 2000;290(5492):767-73.

70. Kordower JH, Bloch J, Ma SY, Chu Y, Palfi S, Roitberg BZ, et al. Lentiviral gene transfer to the nonhuman primate brain. Exp Neurol. 1999;160(1):1-16.

71. Déglon N, Tseng JL, Bensadoun JC, Zurn AD, Arsenijevic Y, Pereira de Almeida L, et al. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson’s disease. Hum Gene Ther. 2000;11(1):179-90.

72. Weissmiller AM, Wu C. Current advances in using neurotrophic factors to treat neurodegenerative disorders. Transl Neurodegener. 2012;1:14.

73. Palfi S, Guruchaga JM, Scott Ralph G, Lepetit H, Lavisse S, Buttery PC, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: A dose escalation, open-label, phase 1/2 trial. Lancet. 2014;383(9923):1138-46.

74. Mochizuki H, Yasuda T, Mouradian MM. Advances in Gene Therapy for Movement Disorders. Neurotherapeutics. 2008;5(2):260-9.

75. D’Mello SR, Heinrich G. Structural and functional identification of regulatory regions and cis elements surrounding the nerve growth factor gene promoter. Brain Res Mol Brain Res. 1991;11(3-4):255-64.

76. Cronin J, Zhang X-Y, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther. 2005;5(4):387-98.

77. Pruunsild P, Kazantseval A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus: Bidirectional transcription, complex splicing, and multiple promoters. Genomics. 2007;90(3):397-406.

78. Davila D, Thibault K, Fiacco TA, Aguillon C. Recent molecular approaches to understanding astrocyte function in vivo. Front Cell Neurosci. 2013;7:272.

79. Truong K, Khorchid A, Ikura M. A fluorescent cassette-based strategy for engineering multiple domain fusion proteins. BMC Biotechnol. 2003;3:8.

80. Recchia A, Rota D, Debetto P, Peroni D, Guidolin D, Negro A, et al. Generation of a alpha-synuclein-based rat model of Parkinson’s disease. Neurobiol Dis. 2008;30(1):8-18.

81. Cartwright M, Martin S, D’Mello S, Heinrich G. The human nerve growth factor gene: structure of the promoter region and expression in L929 fibroblasts. Brain Res Mol Brain Res. 1992;15(1-2):67-75.

82. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O’Malley KL, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet. 1994;4(2):148-54.

83. Longo FM, Massa SM. Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease. Nat Rev Drug Discov. 2013;12(7):507-25.